Vioxx Withdrawal Costs Merck Over $700 Mil. In Third Quarter
This article was originally published in The Pink Sheet Daily
Executive Summary
Impact of COX-2 inhibitor withdrawal reduces Merck’s quarterly earnings by over $550 mil. Merck reaffirms guidance for its major franchises, but Zocor sales are down for the quarter.
You may also be interested in...
Merck Corrects Zocor, Vioxx Impact On Gross Margins
Company says fourth quarter product gross margin is expected to be about 77% instead of the 75% previously reported. The guidance excludes adjustments related to the Vioxx withdrawal.
Merck Corrects Zocor, Vioxx Impact On Gross Margins
Company says fourth quarter product gross margin is expected to be about 77% instead of the 75% previously reported. The guidance excludes adjustments related to the Vioxx withdrawal.
Vytorin Captures 2% Of New Prescriptions In Cholesterol Market
Merck/Schering’s fixed-dose combination is ahead of AstraZeneca’s Crestor at a similar time during its launch, Schering-Plough says. Schering is also pleased with Vytorin’s level of managed care access.